Z. Younossi

Publications1,157
h-index100
Citations54,477
Highly Influential Citations2,332
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • M. Stepanova
  • 287 Publications • 6,498 Citations
  • L. Henry
  • 172 Publications • 6,749 Citations
  • A. Sanyal
  • 847 Publications • 56,738 Citations
  • S. Zeuzem
  • 1,288 Publications • 56,060 Citations
  • Publications
  • Influence
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonalcoholic… Expand
  • 2,982
  • 176
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Abstract This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care. A "Guidance" document is different from a "Guideline." Guidelines are… Expand
  • 1,774
  • 135
  • PDF
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
BACKGROUND & AIMS The spectrum of nonalcoholic fatty liver disease ranges from fatty liver alone to nonalcoholic steatohepatitis. Most previous studies have short follow-up and have not carefully… Expand
  • 2,971
  • 111
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
Aliment Pharmacol Ther 2011; 34: 274–285
  • 2,217
  • 106
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the…
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the… Expand
  • 1,389
  • 103
  • PDF
Sofosbuvir for previously untreated chronic hepatitis C infection.
BACKGROUND In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection. … Expand
  • 1,665
  • 94
  • PDF
The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the…
These recommendations are based on the following: (1) a formal review and analysis of the recently published world literature on the topic [Medline search up to June 2011]; (2) the American College… Expand
  • 1,621
  • 93
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and…
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and… Expand
  • 1,270
  • 80
  • PDF
Telaprevir for retreatment of HCV infection.
BACKGROUND Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin. METHODS In this… Expand
  • 1,571
  • 75
  • PDF
Nonalcoholic steatohepatitis
Opinion statementNonalcoholic steatohepatitis (NASH) is an important medical condition and there is great public health concern related to its increasing incidence and potential implications for the… Expand
  • 919
  • 55
...
1
2
3
4
5
...